Functional hypoxia drives neuroplasticity and neurogenesis via brain erythropoietin.
Debia WakhlooFranziska ScharkowskiYasmina CurtoUmer Javed ButtVikas BansalAgnes A Steixner-KumarLiane WüstefeldAshish RajputSahab ArinradMatthias R ZillmannAnna SeelbachImam HassounaKatharina SchneiderAbdul Qadir IbrahimHauke B WernerHenrik MartensKamilla Woznica MiskowiakSonja M WojcikStefan BonnJuan NacherKlaus-Armin NaveHannelore EhrenreichPublished in: Nature communications (2020)
Erythropoietin (EPO), named after its role in hematopoiesis, is also expressed in mammalian brain. In clinical settings, recombinant EPO treatment has revealed a remarkable improvement of cognition, but underlying mechanisms have remained obscure. Here, we show with a novel line of reporter mice that cognitive challenge induces local/endogenous hypoxia in hippocampal pyramidal neurons, hence enhancing expression of EPO and EPO receptor (EPOR). High-dose EPO administration, amplifying auto/paracrine EPO/EPOR signaling, prompts the emergence of new CA1 neurons and enhanced dendritic spine densities. Single-cell sequencing reveals rapid increase in newly differentiating neurons. Importantly, improved performance on complex running wheels after EPO is imitated by exposure to mild exogenous/inspiratory hypoxia. All these effects depend on neuronal expression of the Epor gene. This suggests a model of neuroplasticity in form of a fundamental regulatory circle, in which neuronal networks-challenged by cognitive tasks-drift into transient hypoxia, thereby triggering neuronal EPO/EPOR expression.
Keyphrases
- cerebral ischemia
- single cell
- poor prognosis
- high dose
- endothelial cells
- spinal cord
- subarachnoid hemorrhage
- binding protein
- brain injury
- low dose
- rna seq
- magnetic resonance imaging
- crispr cas
- resting state
- gene expression
- type diabetes
- spinal cord injury
- multiple sclerosis
- mild cognitive impairment
- insulin resistance
- genome wide identification
- wild type